Curis Lifesciences IPO Subscription Status
Curis Lifesciences IPO subscribed over 5.14x on its Second day till 05.00 PM on 10th November 2025.
- Curis Lifesciences IPO subscription QIB investors’ portion is 8.34x times, while NII subscribed 4.06x times, and RII investors subscribed 3.77x times.
- The company has received bids for 73,59,000 shares against 14,33,000 shares on offer on the Second day.
- Curis Lifesciences IPO subscribed over 5.14x times on day 2.
- Curis Lifesciences IPO subscribed over 3.07x times on day 1.
About the Curis Lifesciences IPO
Curis Lifesciences Limited, founded in 2010, is one of the leading pharmaceutical companies that manufactures a wide range of pharmaceutical products, including Tablets, Capsules, External Preparations, Oral liquids, and Sterile Ophthalmic Ointments. The company gets ready-made goods from manufacturers and distributes them to wholesalers and other clients nationwide. The company had a total of 95 permanent employees as of July 31, 2025.
Curis Lifescience makes medicine in India and abroad under contract or license agreement, as well as for its own brand. In addition to its two own-brand clients in Yemen and Kenya, the firm contracts with more than 100 corporate clients. Moreover, the company consists of a state-of-the-art factory in Sanand, Gujarat, through which they follow strict quality control checks to make sure each of their products is safe and works well.
Curis Lifesciences IPO Company Financial Report
The company reported revenue of ₹49.65 crores in 2025 against ₹35.87 crores in 2024. The company reported a profit of ₹6.11 crores in 2025 against a profit of ₹4.87 crores in 2024.
Curis Lifesciences IPO GMP
Curis Lifesciences IPO GMP was ₹8 as of Monday, 10th November. That indicates the IPO is trading at ₹136 with a ₹8 premium in the grey market against the issue price of ₹128.
